 | • レポートコード：MRC2-11QY11919 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、129ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は第VIII因子欠乏症治療のグローバル市場について調査・分析したレポートです。種類別（血友病A薬、血友病A阻害剤治療、フォンウィルブランド病治療）市場規模、用途別（病院、クリニック、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別第VIII因子欠乏症治療の競争状況、市場シェア ・世界の第VIII因子欠乏症治療市場：種類別市場規模 2015年-2020年（血友病A薬、血友病A阻害剤治療、フォンウィルブランド病治療） ・世界の第VIII因子欠乏症治療市場：種類別市場規模予測 2021年-2026年（血友病A薬、血友病A阻害剤治療、フォンウィルブランド病治療） ・世界の第VIII因子欠乏症治療市場：用途別市場規模 2015年-2020年（病院、クリニック、その他） ・世界の第VIII因子欠乏症治療市場：用途別市場規模予測 2021年-2026年（病院、クリニック、その他） ・北米の第VIII因子欠乏症治療市場分析：米国、カナダ ・ヨーロッパの第VIII因子欠乏症治療市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの第VIII因子欠乏症治療市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の第VIII因子欠乏症治療市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの第VIII因子欠乏症治療市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Pfizer、Takeda、Bayer HealthCare、CSL、Grifols、Novo Nordisk、F. Hoffmann-La Roche、Kedrion、Octapharma、Biogen Idec、BioMarin Pharmaceutical、Sangamo Therapeutics、Spark Therapeutics、Swedish Orphan Biovitrum、Uniqure NV、Amarna Therapeutics、Dimension Therapeutics ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Factor VIII is an essential blood-clotting protein, which is also known as an antihemophilic factor. In individuals, factor VIII is encoded by F8 gene. Defects in F8 gene lead to hemophilia A, a recessive X-linked coagulation disorder. Factor VIII is generated in liver sinusoidal cells and endothelial cells outside the liver across the body. This protein mixes in the bloodstream in an inactive form, and binds to another molecule called von Willebrand factor, until a damage to blood vessels occur. In response to injury, coagulation factor VIII gets activated and separates from von Willebrand factor.
The global hemophilia A drugs market segment accounted for the majority market share and will continue to dominate the factor 8 deficiency treatment market for the next few years. Some of the major factors responsible for the market segment’s growth is the growing incidence of hemophilia A, the development of novel drugs with extended action, and the increased adoption of prophylactic treatment. Additionally, growing demand for novel recombinant extended half-life products, the emergence of monoclonal antibodies and gene therapy products, and launch of plasma-derived products for recombinant factor VIII at low costs, will also further drive the growth of the factor VIII deficiency treatment market.
Market Analysis and Insights: Global Factor VIII Deficiency Treatment Market
The global Factor VIII Deficiency Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Factor VIII Deficiency Treatment Scope and Market Size
Factor VIII Deficiency Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Factor VIII Deficiency Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Pfizer
Takeda
Bayer HealthCare
CSL
Grifols
Novo Nordisk
F. Hoffmann-La Roche
Kedrion
Octapharma
Biogen Idec
BioMarin Pharmaceutical
Sangamo Therapeutics
Spark Therapeutics
Swedish Orphan Biovitrum
Uniqure NV
Amarna Therapeutics
Dimension Therapeutics
Market segment by Type, the product can be split into
Hemophilia A Drugs
Hemophilia A Inhibitors Treatment
Von Willebrand Disease Treatment
Market segment by Application, split into
Hospitals
Clinics
Other
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Factor VIII Deficiency Treatment Revenue
1.4 Market by Type
1.4.1 Global Factor VIII Deficiency Treatment Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Hemophilia A Drugs
1.4.3 Hemophilia A Inhibitors Treatment
1.4.4 Von Willebrand Disease Treatment
1.5 Market by Application
1.5.1 Global Factor VIII Deficiency Treatment Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Other
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Factor VIII Deficiency Treatment Market Perspective (2015-2026)
2.2 Global Factor VIII Deficiency Treatment Growth Trends by Regions
2.2.1 Factor VIII Deficiency Treatment Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Factor VIII Deficiency Treatment Historic Market Share by Regions (2015-2020)
2.2.3 Factor VIII Deficiency Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Factor VIII Deficiency Treatment Market Growth Strategy
2.3.6 Primary Interviews with Key Factor VIII Deficiency Treatment Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Factor VIII Deficiency Treatment Players by Market Size
3.1.1 Global Top Factor VIII Deficiency Treatment Players by Revenue (2015-2020)
3.1.2 Global Factor VIII Deficiency Treatment Revenue Market Share by Players (2015-2020)
3.1.3 Global Factor VIII Deficiency Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Factor VIII Deficiency Treatment Market Concentration Ratio
3.2.1 Global Factor VIII Deficiency Treatment Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Factor VIII Deficiency Treatment Revenue in 2019
3.3 Factor VIII Deficiency Treatment Key Players Head office and Area Served
3.4 Key Players Factor VIII Deficiency Treatment Product Solution and Service
3.5 Date of Enter into Factor VIII Deficiency Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Factor VIII Deficiency Treatment Historic Market Size by Type (2015-2020)
4.2 Global Factor VIII Deficiency Treatment Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Factor VIII Deficiency Treatment Market Size by Application (2015-2020)
5.2 Global Factor VIII Deficiency Treatment Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Factor VIII Deficiency Treatment Market Size (2015-2020)
6.2 Factor VIII Deficiency Treatment Key Players in North America (2019-2020)
6.3 North America Factor VIII Deficiency Treatment Market Size by Type (2015-2020)
6.4 North America Factor VIII Deficiency Treatment Market Size by Application (2015-2020)
7 Europe
7.1 Europe Factor VIII Deficiency Treatment Market Size (2015-2020)
7.2 Factor VIII Deficiency Treatment Key Players in Europe (2019-2020)
7.3 Europe Factor VIII Deficiency Treatment Market Size by Type (2015-2020)
7.4 Europe Factor VIII Deficiency Treatment Market Size by Application (2015-2020)
8 China
8.1 China Factor VIII Deficiency Treatment Market Size (2015-2020)
8.2 Factor VIII Deficiency Treatment Key Players in China (2019-2020)
8.3 China Factor VIII Deficiency Treatment Market Size by Type (2015-2020)
8.4 China Factor VIII Deficiency Treatment Market Size by Application (2015-2020)
9 Japan
9.1 Japan Factor VIII Deficiency Treatment Market Size (2015-2020)
9.2 Factor VIII Deficiency Treatment Key Players in Japan (2019-2020)
9.3 Japan Factor VIII Deficiency Treatment Market Size by Type (2015-2020)
9.4 Japan Factor VIII Deficiency Treatment Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Factor VIII Deficiency Treatment Market Size (2015-2020)
10.2 Factor VIII Deficiency Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Factor VIII Deficiency Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Factor VIII Deficiency Treatment Market Size by Application (2015-2020)
11 India
11.1 India Factor VIII Deficiency Treatment Market Size (2015-2020)
11.2 Factor VIII Deficiency Treatment Key Players in India (2019-2020)
11.3 India Factor VIII Deficiency Treatment Market Size by Type (2015-2020)
11.4 India Factor VIII Deficiency Treatment Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Factor VIII Deficiency Treatment Market Size (2015-2020)
12.2 Factor VIII Deficiency Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Factor VIII Deficiency Treatment Market Size by Type (2015-2020)
12.4 Central & South America Factor VIII Deficiency Treatment Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Pfizer
13.1.1 Pfizer Company Details
13.1.2 Pfizer Business Overview
13.1.3 Pfizer Factor VIII Deficiency Treatment Introduction
13.1.4 Pfizer Revenue in Factor VIII Deficiency Treatment Business (2015-2020))
13.1.5 Pfizer Recent Development
13.2 Takeda
13.2.1 Takeda Company Details
13.2.2 Takeda Business Overview
13.2.3 Takeda Factor VIII Deficiency Treatment Introduction
13.2.4 Takeda Revenue in Factor VIII Deficiency Treatment Business (2015-2020)
13.2.5 Takeda Recent Development
13.3 Bayer HealthCare
13.3.1 Bayer HealthCare Company Details
13.3.2 Bayer HealthCare Business Overview
13.3.3 Bayer HealthCare Factor VIII Deficiency Treatment Introduction
13.3.4 Bayer HealthCare Revenue in Factor VIII Deficiency Treatment Business (2015-2020)
13.3.5 Bayer HealthCare Recent Development
13.4 CSL
13.4.1 CSL Company Details
13.4.2 CSL Business Overview
13.4.3 CSL Factor VIII Deficiency Treatment Introduction
13.4.4 CSL Revenue in Factor VIII Deficiency Treatment Business (2015-2020)
13.4.5 CSL Recent Development
13.5 Grifols
13.5.1 Grifols Company Details
13.5.2 Grifols Business Overview
13.5.3 Grifols Factor VIII Deficiency Treatment Introduction
13.5.4 Grifols Revenue in Factor VIII Deficiency Treatment Business (2015-2020)
13.5.5 Grifols Recent Development
13.6 Novo Nordisk
13.6.1 Novo Nordisk Company Details
13.6.2 Novo Nordisk Business Overview
13.6.3 Novo Nordisk Factor VIII Deficiency Treatment Introduction
13.6.4 Novo Nordisk Revenue in Factor VIII Deficiency Treatment Business (2015-2020)
13.6.5 Novo Nordisk Recent Development
13.7 F. Hoffmann-La Roche
13.7.1 F. Hoffmann-La Roche Company Details
13.7.2 F. Hoffmann-La Roche Business Overview
13.7.3 F. Hoffmann-La Roche Factor VIII Deficiency Treatment Introduction
13.7.4 F. Hoffmann-La Roche Revenue in Factor VIII Deficiency Treatment Business (2015-2020)
13.7.5 F. Hoffmann-La Roche Recent Development
13.8 Kedrion
13.8.1 Kedrion Company Details
13.8.2 Kedrion Business Overview
13.8.3 Kedrion Factor VIII Deficiency Treatment Introduction
13.8.4 Kedrion Revenue in Factor VIII Deficiency Treatment Business (2015-2020)
13.8.5 Kedrion Recent Development
13.9 Octapharma
13.9.1 Octapharma Company Details
13.9.2 Octapharma Business Overview
13.9.3 Octapharma Factor VIII Deficiency Treatment Introduction
13.9.4 Octapharma Revenue in Factor VIII Deficiency Treatment Business (2015-2020)
13.9.5 Octapharma Recent Development
13.10 Biogen Idec
13.10.1 Biogen Idec Company Details
13.10.2 Biogen Idec Business Overview
13.10.3 Biogen Idec Factor VIII Deficiency Treatment Introduction
13.10.4 Biogen Idec Revenue in Factor VIII Deficiency Treatment Business (2015-2020)
13.10.5 Biogen Idec Recent Development
13.11 BioMarin Pharmaceutical
10.11.1 BioMarin Pharmaceutical Company Details
10.11.2 BioMarin Pharmaceutical Business Overview
10.11.3 BioMarin Pharmaceutical Factor VIII Deficiency Treatment Introduction
10.11.4 BioMarin Pharmaceutical Revenue in Factor VIII Deficiency Treatment Business (2015-2020)
10.11.5 BioMarin Pharmaceutical Recent Development
13.12 Sangamo Therapeutics
10.12.1 Sangamo Therapeutics Company Details
10.12.2 Sangamo Therapeutics Business Overview
10.12.3 Sangamo Therapeutics Factor VIII Deficiency Treatment Introduction
10.12.4 Sangamo Therapeutics Revenue in Factor VIII Deficiency Treatment Business (2015-2020)
10.12.5 Sangamo Therapeutics Recent Development
13.13 Spark Therapeutics
10.13.1 Spark Therapeutics Company Details
10.13.2 Spark Therapeutics Business Overview
10.13.3 Spark Therapeutics Factor VIII Deficiency Treatment Introduction
10.13.4 Spark Therapeutics Revenue in Factor VIII Deficiency Treatment Business (2015-2020)
10.13.5 Spark Therapeutics Recent Development
13.14 Swedish Orphan Biovitrum
10.14.1 Swedish Orphan Biovitrum Company Details
10.14.2 Swedish Orphan Biovitrum Business Overview
10.14.3 Swedish Orphan Biovitrum Factor VIII Deficiency Treatment Introduction
10.14.4 Swedish Orphan Biovitrum Revenue in Factor VIII Deficiency Treatment Business (2015-2020)
10.14.5 Swedish Orphan Biovitrum Recent Development
13.15 Uniqure NV
10.15.1 Uniqure NV Company Details
10.15.2 Uniqure NV Business Overview
10.15.3 Uniqure NV Factor VIII Deficiency Treatment Introduction
10.15.4 Uniqure NV Revenue in Factor VIII Deficiency Treatment Business (2015-2020)
10.15.5 Uniqure NV Recent Development
13.16 Amarna Therapeutics
10.16.1 Amarna Therapeutics Company Details
10.16.2 Amarna Therapeutics Business Overview
10.16.3 Amarna Therapeutics Factor VIII Deficiency Treatment Introduction
10.16.4 Amarna Therapeutics Revenue in Factor VIII Deficiency Treatment Business (2015-2020)
10.16.5 Amarna Therapeutics Recent Development
13.17 Dimension Therapeutics
10.17.1 Dimension Therapeutics Company Details
10.17.2 Dimension Therapeutics Business Overview
10.17.3 Dimension Therapeutics Factor VIII Deficiency Treatment Introduction
10.17.4 Dimension Therapeutics Revenue in Factor VIII Deficiency Treatment Business (2015-2020)
10.17.5 Dimension Therapeutics Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Factor VIII Deficiency Treatment Key Market Segments
Table 2. Key Players Covered: Ranking by Factor VIII Deficiency Treatment Revenue
Table 3. Ranking of Global Top Factor VIII Deficiency Treatment Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Factor VIII Deficiency Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Hemophilia A Drugs
Table 6. Key Players of Hemophilia A Inhibitors Treatment
Table 7. Key Players of Von Willebrand Disease Treatment
Table 8. Global Factor VIII Deficiency Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 9. Global Factor VIII Deficiency Treatment Market Size by Regions (US$ Million): 2020 VS 2026
Table 10. Global Factor VIII Deficiency Treatment Market Size by Regions (2015-2020) (US$ Million)
Table 11. Global Factor VIII Deficiency Treatment Market Share by Regions (2015-2020)
Table 12. Global Factor VIII Deficiency Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 13. Global Factor VIII Deficiency Treatment Market Share by Regions (2021-2026)
Table 14. Market Top Trends
Table 15. Key Drivers: Impact Analysis
Table 16. Key Challenges
Table 17. Factor VIII Deficiency Treatment Market Growth Strategy
Table 18. Main Points Interviewed from Key Factor VIII Deficiency Treatment Players
Table 19. Global Factor VIII Deficiency Treatment Revenue by Players (2015-2020) (Million US$)
Table 20. Global Factor VIII Deficiency Treatment Market Share by Players (2015-2020)
Table 21. Global Top Factor VIII Deficiency Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Factor VIII Deficiency Treatment as of 2019)
Table 22. Global Factor VIII Deficiency Treatment by Players Market Concentration Ratio (CR5 and HHI)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Factor VIII Deficiency Treatment Product Solution and Service
Table 25. Date of Enter into Factor VIII Deficiency Treatment Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Factor VIII Deficiency Treatment Market Size by Type (2015-2020) (Million US$)
Table 28. Global Factor VIII Deficiency Treatment Market Size Share by Type (2015-2020)
Table 29. Global Factor VIII Deficiency Treatment Revenue Market Share by Type (2021-2026)
Table 30. Global Factor VIII Deficiency Treatment Market Size Share by Application (2015-2020)
Table 31. Global Factor VIII Deficiency Treatment Market Size by Application (2015-2020) (Million US$)
Table 32. Global Factor VIII Deficiency Treatment Market Size Share by Application (2021-2026)
Table 33. North America Key Players Factor VIII Deficiency Treatment Revenue (2019-2020) (Million US$)
Table 34. North America Key Players Factor VIII Deficiency Treatment Market Share (2019-2020)
Table 35. North America Factor VIII Deficiency Treatment Market Size by Type (2015-2020) (Million US$)
Table 36. North America Factor VIII Deficiency Treatment Market Share by Type (2015-2020)
Table 37. North America Factor VIII Deficiency Treatment Market Size by Application (2015-2020) (Million US$)
Table 38. North America Factor VIII Deficiency Treatment Market Share by Application (2015-2020)
Table 39. Europe Key Players Factor VIII Deficiency Treatment Revenue (2019-2020) (Million US$)
Table 40. Europe Key Players Factor VIII Deficiency Treatment Market Share (2019-2020)
Table 41. Europe Factor VIII Deficiency Treatment Market Size by Type (2015-2020) (Million US$)
Table 42. Europe Factor VIII Deficiency Treatment Market Share by Type (2015-2020)
Table 43. Europe Factor VIII Deficiency Treatment Market Size by Application (2015-2020) (Million US$)
Table 44. Europe Factor VIII Deficiency Treatment Market Share by Application (2015-2020)
Table 45. China Key Players Factor VIII Deficiency Treatment Revenue (2019-2020) (Million US$)
Table 46. China Key Players Factor VIII Deficiency Treatment Market Share (2019-2020)
Table 47. China Factor VIII Deficiency Treatment Market Size by Type (2015-2020) (Million US$)
Table 48. China Factor VIII Deficiency Treatment Market Share by Type (2015-2020)
Table 49. China Factor VIII Deficiency Treatment Market Size by Application (2015-2020) (Million US$)
Table 50. China Factor VIII Deficiency Treatment Market Share by Application (2015-2020)
Table 51. Japan Key Players Factor VIII Deficiency Treatment Revenue (2019-2020) (Million US$)
Table 52. Japan Key Players Factor VIII Deficiency Treatment Market Share (2019-2020)
Table 53. Japan Factor VIII Deficiency Treatment Market Size by Type (2015-2020) (Million US$)
Table 54. Japan Factor VIII Deficiency Treatment Market Share by Type (2015-2020)
Table 55. Japan Factor VIII Deficiency Treatment Market Size by Application (2015-2020) (Million US$)
Table 56. Japan Factor VIII Deficiency Treatment Market Share by Application (2015-2020)
Table 57. Southeast Asia Key Players Factor VIII Deficiency Treatment Revenue (2019-2020) (Million US$)
Table 58. Southeast Asia Key Players Factor VIII Deficiency Treatment Market Share (2019-2020)
Table 59. Southeast Asia Factor VIII Deficiency Treatment Market Size by Type (2015-2020) (Million US$)
Table 60. Southeast Asia Factor VIII Deficiency Treatment Market Share by Type (2015-2020)
Table 61. Southeast Asia Factor VIII Deficiency Treatment Market Size by Application (2015-2020) (Million US$)
Table 62. Southeast Asia Factor VIII Deficiency Treatment Market Share by Application (2015-2020)
Table 63. India Key Players Factor VIII Deficiency Treatment Revenue (2019-2020) (Million US$)
Table 64. India Key Players Factor VIII Deficiency Treatment Market Share (2019-2020)
Table 65. India Factor VIII Deficiency Treatment Market Size by Type (2015-2020) (Million US$)
Table 66. India Factor VIII Deficiency Treatment Market Share by Type (2015-2020)
Table 67. India Factor VIII Deficiency Treatment Market Size by Application (2015-2020) (Million US$)
Table 68. India Factor VIII Deficiency Treatment Market Share by Application (2015-2020)
Table 69. Central & South America Key Players Factor VIII Deficiency Treatment Revenue (2019-2020) (Million US$)
Table 70. Central & South America Key Players Factor VIII Deficiency Treatment Market Share (2019-2020)
Table 71. Central & South America Factor VIII Deficiency Treatment Market Size by Type (2015-2020) (Million US$)
Table 72. Central & South America Factor VIII Deficiency Treatment Market Share by Type (2015-2020)
Table 73. Central & South America Factor VIII Deficiency Treatment Market Size by Application (2015-2020) (Million US$)
Table 74. Central & South America Factor VIII Deficiency Treatment Market Share by Application (2015-2020)
Table 75. Pfizer Company Details
Table 76. Pfizer Business Overview
Table 77. Pfizer Product
Table 78. Pfizer Revenue in Factor VIII Deficiency Treatment Business (2015-2020) (Million US$)
Table 79. Pfizer Recent Development
Table 80. Takeda Company Details
Table 81. Takeda Business Overview
Table 82. Takeda Product
Table 83. Takeda Revenue in Factor VIII Deficiency Treatment Business (2015-2020) (Million US$)
Table 84. Takeda Recent Development
Table 85. Bayer HealthCare Company Details
Table 86. Bayer HealthCare Business Overview
Table 87. Bayer HealthCare Product
Table 88. Bayer HealthCare Revenue in Factor VIII Deficiency Treatment Business (2015-2020) (Million US$)
Table 89. Bayer HealthCare Recent Development
Table 90. CSL Company Details
Table 91. CSL Business Overview
Table 92. CSL Product
Table 93. CSL Revenue in Factor VIII Deficiency Treatment Business (2015-2020) (Million US$)
Table 94. CSL Recent Development
Table 95. Grifols Company Details
Table 96. Grifols Business Overview
Table 97. Grifols Product
Table 98. Grifols Revenue in Factor VIII Deficiency Treatment Business (2015-2020) (Million US$)
Table 99. Grifols Recent Development
Table 100. Novo Nordisk Company Details
Table 101. Novo Nordisk Business Overview
Table 102. Novo Nordisk Product
Table 103. Novo Nordisk Revenue in Factor VIII Deficiency Treatment Business (2015-2020) (Million US$)
Table 104. Novo Nordisk Recent Development
Table 105. F. Hoffmann-La Roche Company Details
Table 106. F. Hoffmann-La Roche Business Overview
Table 107. F. Hoffmann-La Roche Product
Table 108. F. Hoffmann-La Roche Revenue in Factor VIII Deficiency Treatment Business (2015-2020) (Million US$)
Table 109. F. Hoffmann-La Roche Recent Development
Table 110. Kedrion Business Overview
Table 111. Kedrion Product
Table 112. Kedrion Company Details
Table 113. Kedrion Revenue in Factor VIII Deficiency Treatment Business (2015-2020) (Million US$)
Table 114. Kedrion Recent Development
Table 115. Octapharma Company Details
Table 116. Octapharma Business Overview
Table 117. Octapharma Product
Table 118. Octapharma Revenue in Factor VIII Deficiency Treatment Business (2015-2020) (Million US$)
Table 119. Octapharma Recent Development
Table 120. Biogen Idec Company Details
Table 121. Biogen Idec Business Overview
Table 122. Biogen Idec Product
Table 123. Biogen Idec Revenue in Factor VIII Deficiency Treatment Business (2015-2020) (Million US$)
Table 124. Biogen Idec Recent Development
Table 125. BioMarin Pharmaceutical Company Details
Table 126. BioMarin Pharmaceutical Business Overview
Table 127. BioMarin Pharmaceutical Product
Table 128. BioMarin Pharmaceutical Revenue in Factor VIII Deficiency Treatment Business (2015-2020) (Million US$)
Table 129. BioMarin Pharmaceutical Recent Development
Table 130. Sangamo Therapeutics Company Details
Table 131. Sangamo Therapeutics Business Overview
Table 132. Sangamo Therapeutics Product
Table 133. Sangamo Therapeutics Revenue in Factor VIII Deficiency Treatment Business (2015-2020) (Million US$)
Table 134. Sangamo Therapeutics Recent Development
Table 135. Spark Therapeutics Company Details
Table 136. Spark Therapeutics Business Overview
Table 137. Spark Therapeutics Product
Table 138. Spark Therapeutics Revenue in Factor VIII Deficiency Treatment Business (2015-2020) (Million US$)
Table 139. Spark Therapeutics Recent Development
Table 140. Swedish Orphan Biovitrum Company Details
Table 141. Swedish Orphan Biovitrum Business Overview
Table 142. Swedish Orphan Biovitrum Product
Table 143. Swedish Orphan Biovitrum Revenue in Factor VIII Deficiency Treatment Business (2015-2020) (Million US$)
Table 144. Swedish Orphan Biovitrum Recent Development
Table 145. Uniqure NV Company Details
Table 146. Uniqure NV Business Overview
Table 147. Uniqure NV Product
Table 148. Uniqure NV Revenue in Factor VIII Deficiency Treatment Business (2015-2020) (Million US$)
Table 149. Uniqure NV Recent Development
Table 150. Amarna Therapeutics Company Details
Table 151. Amarna Therapeutics Business Overview
Table 152. Amarna Therapeutics Product
Table 153. Amarna Therapeutics Revenue in Factor VIII Deficiency Treatment Business (2015-2020) (Million US$)
Table 154. Amarna Therapeutics Recent Development
Table 155. Dimension Therapeutics Company Details
Table 156. Dimension Therapeutics Business Overview
Table 157. Dimension Therapeutics Product
Table 158. Dimension Therapeutics Revenue in Factor VIII Deficiency Treatment Business (2015-2020) (Million US$)
Table 159. Dimension Therapeutics Recent Development
Table 160. Research Programs/Design for This Report
Table 161. Key Data Information from Secondary Sources
Table 162. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Factor VIII Deficiency Treatment Market Share by Type: 2020 VS 2026
Figure 2. Hemophilia A Drugs Features
Figure 3. Hemophilia A Inhibitors Treatment Features
Figure 4. Von Willebrand Disease Treatment Features
Figure 5. Global Factor VIII Deficiency Treatment Market Share by Application: 2020 VS 2026
Figure 6. Hospitals Case Studies
Figure 7. Clinics Case Studies
Figure 8. Other Case Studies
Figure 9. Factor VIII Deficiency Treatment Report Years Considered
Figure 10. Global Factor VIII Deficiency Treatment Market Size YoY Growth 2015-2026 (US$ Million)
Figure 11. Global Factor VIII Deficiency Treatment Market Share by Regions: 2020 VS 2026
Figure 12. Global Factor VIII Deficiency Treatment Market Share by Regions (2021-2026)
Figure 13. Porter's Five Forces Analysis
Figure 14. Global Factor VIII Deficiency Treatment Market Share by Players in 2019
Figure 15. Global Top Factor VIII Deficiency Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Factor VIII Deficiency Treatment as of 2019
Figure 16. The Top 10 and 5 Players Market Share by Factor VIII Deficiency Treatment Revenue in 2019
Figure 17. North America Factor VIII Deficiency Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Europe Factor VIII Deficiency Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. China Factor VIII Deficiency Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Japan Factor VIII Deficiency Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Southeast Asia Factor VIII Deficiency Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. India Factor VIII Deficiency Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Central & South America Factor VIII Deficiency Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Bottom-up and Top-down Approaches for This Report
Figure 25. Data Triangulation
Figure 26. Key Executives Interviewed
第IX因子欠乏症治療の世界市場（～2026年） Factor IX (or Christmas factor) is one of the serine proteases of the coagulation system; it belongs to peptidase family S1. Deficiency of this protein causes hemophilia B. In this market study, analysts have estimated the prophylaxis segment to dominate the factor IX deficiency treatment market dur…- 成長ホルモン欠乏症治療の世界市場（～2026年） Growth hormone deficiency (GHD) is a medical condition characterized by insufficient production of somatropin, a growth hormone, from the anterior pituitary gland which is responsible for the growth and cell reproduction. The primary factor contributing to the growth of global growth hormone deficie…
- チロシンヒドロキシラーゼ欠損症治療の世界市場（～2026年） The Tyrosine Hydroxylase Deficiency is also known as recessive dopa-responsive dystonia and is a rare genetic disorder. In the Tyrosine Hydroxylase Deficiency, there is lack of enzymes which are involved in converting amino acid tyrosine to L-dopa. A wide range of symptoms can be associated with the…
- ビタミン欠乏症治療の世界市場（～2026年） Vitamin deficiency, also called as hypovitaminosis, is primarily caused by malnutrition. The global vitamin deficiency treatment market is highly fragmented with large number of local as well as strong players. Market Analysis and Insights: Global Vitamin Deficiency Treatment Market The global Vitam…
- 亜鉛欠乏症治療の世界市場（～2026年） Fill zinc, it is the microelement zinc that compensatory human body needs, filling zinc is in human body growth development, immunity, vitamin to wait to having extremely important effect. Market Analysis and Insights: Global Zinc Deficiency Treatment Market The global Zinc Deficiency Treatment mark…